Will Gilteritinib be officially included in medical insurance in 2025?

As of2025, although Gilitinib (Gilteritinib) has been launched in China, it has not yet been included in the medical insurance system. Due to the high price of this drug, the fact that it is not included in medical insurance means that patients may face certain financial pressure and difficulties in purchasing the drug when purchasing it domestically. Giritinib is mainly used to treat diseases such as acute myeloid leukemia (AML). Although it plays an important clinical role, the lack of medical insurance support makes it a heavy burden for many patients.

Although giritinib is not included in the domestic medical insurance system, patients can still choose to purchase it through the hospital. However, given the higher price, especially for the original version, patients may need to pay extra, which may also make it unaffordable for some patients. There are different versions of the original drug of giritinib in the international market, the most common ones are the European version and the Hong Kong version, which are extremely expensive. The price of the Hong Kong version of giritinib can be as high as 100,000 yuan. For most patients, this price is very unfavorable and may lead them to choose other treatment options.

In contrast, giritinib also has generic versions available in foreign markets, especially the Lao version. The price of the Lao version of giritinib is significantly lower than the original drug, only more than 1,000 to 2,000 yuan, which allows many patients with limited economic conditions to choose this drug. The ingredients of generic drugs are consistent with the original drugs, and when purchased through formal channels, the quality and efficacy of the drugs can usually be guaranteed, making them the first choice for some patients. The emergence of generic drugs has greatly reduced the financial burden on patients.

For giritinib, which has not been included in domestic medical insurance, patients need to comprehensively consider their economic status, medical insurance reimbursement status, and the efficacy of the drug when choosing treatment. When not covered by medical insurance, the price of original drugs may make patients unable to afford them, and generic drugs have become a reasonable and economical alternative. Although generic drugs are more affordable, patients should still make sure to purchase them through reliable channels to ensure drug quality and avoid side effects or insufficient efficacy.

Reference materials:https://www.xospata.com/